Risankizumab Efficacy in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Remission: A Case Report on Rheumatologic and Dermatologic Disease Manifestations with Literature Review

<div>Disease activity indexes during Risankizumab therapy, measured in weeks after therapy initiation. DAPSA, disease activity in psoriatic arthritis; PtGA, patient global assessment; PASI, psoriasis area and severity index; and BSA, body surface area.</div>

Case Reports in Immunology

fig2

Figure 2

Figure 2: Risankizumab Efficacy in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Remission: A Case Report on Rheumatologic and Dermatologic Disease Manifestations with Literature Review 

Figure 2 | Risankizumab Efficacy in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Remission: A Case Report on Rheumatologic and Dermatologic Disease Manifestations with Literature Review 